These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19538112)

  • 61. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.
    Ramsay ME; Andrews NJ; Trotter CL; Kaczmarski EB; Miller E
    BMJ; 2003 Feb; 326(7385):365-6. PubMed ID: 12586669
    [No Abstract]   [Full Text] [Related]  

  • 62. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.
    Ramsay ME; Andrews N; Kaczmarski EB; Miller E
    Lancet; 2001 Jan; 357(9251):195-6. PubMed ID: 11213098
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006.
    Kinlin LM; Jamieson F; Brown EM; Brown S; Rawte P; Dolman S; Drews SJ; Fisman DN
    Vaccine; 2009 Mar; 27(11):1735-40. PubMed ID: 19186206
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study.
    Campbell H; Andrews N; Parikh SR; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME; Ladhani SN
    Lancet Child Adolesc Health; 2022 Feb; 6(2):96-105. PubMed ID: 34883094
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine.
    Kristiansen PA; Diomandé F; Wei SC; Ouédraogo R; Sangaré L; Sanou I; Kandolo D; Kaboré P; Clark TA; Ouédraogo AS; Absatou KB; Ouédraogo CD; Hassan-King M; Thomas JD; Hatcher C; Djingarey M; Messonnier N; Préziosi MP; LaForce M; Caugant DA
    Clin Vaccine Immunol; 2011 Mar; 18(3):435-43. PubMed ID: 21228139
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Control of invasive meningococcal disease: is it achievable?
    Marshall H; Wang B; Wesselingh S; Snape M; Pollard AJ
    Int J Evid Based Healthc; 2016 Mar; 14(1):3-14. PubMed ID: 26126001
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Meningococcal group B vaccines.
    Findlow J
    Hum Vaccin Immunother; 2013 Jun; 9(6):1387-8. PubMed ID: 23732894
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Conjugate versus polysaccharide meningococcal vaccine.
    Rashid H; Booy R; Shafi S; Haworth E
    Lancet Infect Dis; 2008 Apr; 8(4):215. PubMed ID: 18353262
    [No Abstract]   [Full Text] [Related]  

  • 72. The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012.
    Sadarangani M; Scheifele DW; Halperin SA; Vaudry W; Le Saux N; Tsang R; Bettinger JA;
    Clin Infect Dis; 2014 Nov; 59(9):1208-15. PubMed ID: 25069868
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
    Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region.
    Soriano-Gabarró M; Wolter J; Hogea C; Vyse A
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):761-74. PubMed ID: 21905785
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
    van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
    Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Public Health Impact After the Introduction of PsA-TT: The First 4 Years.
    Diomandé FV; Djingarey MH; Daugla DM; Novak RT; Kristiansen PA; Collard JM; Gamougam K; Kandolo D; Mbakuliyemo N; Mayer L; Stuart J; Clark T; Tevi-Benissan C; Perea WA; Preziosi MP; Marc LaForce F; Caugant D; Messonnier N; Walker O; Greenwood B
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S467-72. PubMed ID: 26553676
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Meningococcal serogroup a avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom.
    Joseph H; Miller E; Dawson M; Andrews N; Feavers I; Borrow R
    J Infect Dis; 2001 Sep; 184(5):661-2. PubMed ID: 11494176
    [No Abstract]   [Full Text] [Related]  

  • 78. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae.
    Trotter CL; McVernon J; Ramsay ME; Whitney CG; Mulholland EK; Goldblatt D; Hombach J; Kieny MP;
    Vaccine; 2008 Aug; 26(35):4434-45. PubMed ID: 18617296
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines.
    Alderson MR; LaForce FM; Sobanjo-Ter Meulen A; Hwang A; Preziosi MP; Klugman KP
    J Infect Dis; 2019 Oct; 220(220 Suppl 4):S274-S278. PubMed ID: 31671447
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.
    Warshaw MG; Siberry GK; Williams P; Decker MD; Jean-Philippe P; Lujan-Zilbermann J
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e69-e74. PubMed ID: 28339668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.